Immunogenicity and protective efficacy of recombinant Leptospira immunoglobulin-like protein B (rLigB) in a hamster challenge model

Yan, Weiwei; Faisal, Syed M.; McDonough, Sean P.; Divers, Thomas J.; Barr, Stephen C.; Chang, Chia‐Ming; Pan, Ming; Chang, Yung-Fu

doi:10.1016/j.micinf.2008.11.008

Cited by 88 publications

(77 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The importance of the humoral immune response induced by recombinant Lig proteins is unclear. Several authors have associated high antibody titers with protection against lethal infection (26,(29)(30)(31). In contrast, a recent study suggested that protection by LigA was not due solely to the humoral immune response induced by the protein or its fractions (32).…”

Section: Discussionmentioning

confidence: 98%

“…However, the mechanism of Lig protein-mediated protection has not been elucidated. Previous studies examined the ability of Lig proteins to confer protection (24,26,(29)(30)(31)(32)37), but the results were inconclusive in several cases because of the animal models that were used and the low virulence of the challenge strains. In our study, we used the classic animal model of leptospirosis, the golden Syrian hamster, and 10 1 leptospires (5 ϫ LD 50 ) of a highly virulent strain in our heterologous challenge experiment.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Conserved Region of Leptospiral Immunoglobulin-Like A and B Proteins as a DNA Vaccine Elicits a Prophylactic Immune Response against Leptospirosis

Forster¹,

Hartwig²,

Seixas³

et al. 2013

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

A Conserved Region of Leptospiral Immunoglobulin-Like A and B Proteins as a DNA Vaccine Elicits a Prophylactic Immune Response against Leptospirosis

Forster¹,

Hartwig²,

Seixas³

et al. 2013

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

“…Three vaccination experiments were conducted, including one to test IgG antibody production following immunization and two to test vaccine efficacy using a hepatic challenge model of amebiasis (described below). The immunizations were performed by adapting a protocol used by Yan et al (28). Hamsters were immunized with four weekly intraperitoneal injections, each comprised of an emulsion of 100 l of saline containing 50 g of each EhMSP-1 protein fragment, 50 l of complete Freund's adjuvant, and 50 l of incomplete Freund's adjuvant.…”

Section: Methodsmentioning

confidence: 99%

Immunization with the Entamoeba histolytica Surface Metalloprotease EhMSP-1 Protects Hamsters from Amebic Liver Abscess

et al. 2015

View full text Add to dashboard Cite

Diarrhea and amebic liver abscesses due to invasive Entamoeba histolytica infections are an important cause of morbidity and mortality in the developing world. Entamoeba histolytica adherence and cell migration, two phenotypes linked to virulence, are both aberrant in trophozoites deficient in the metallosurface protease EhMSP-1, which is a homologue of the Leishmania vaccine candidate leishmanolysin (GP63). We examined the potential of EhMSP-1 for use as a vaccine antigen to protect against amebic liver abscesses. First, existing serum samples from South Africans naturally infected with E. histolytica were examined by enzyme-linked immunosorbent assay (ELISA) for the presence of EhMSP-1-specific IgG. Nine of 12 (75%) people with anti-E. histolytica IgG also had EhMSP-1-specific IgG antibodies. We next used a hamster model of amebic liver abscess to determine the effect of immunization with a mixture of four recombinant EhMSP-1 protein fragments. EhMSP-1 immunization stimulated a robust IgG antibody response. Furthermore, EhMSP-1 immunization of hamsters reduced development of severe amebic liver abscesses following intrahepatic injection of E. histolytica by a combined rate of 68% in two independent animal experiments. Purified IgG from immunized compared to control animals bound to the surface of E. histolytica trophozoites and accelerated amebic lysis via activation of the classical complement cascade. We concluded that EhMSP-1 is a promising antigen that warrants further study to determine its full potential as a target for therapy and/or prevention of invasive amebiasis. Infectious diarrhea is the second most common cause of death in children under 5 years of age (1). Entamoeba histolytica, the enteric ameba that causes invasive amebiasis, was the most common intestinal parasite identified in children between 2 and 5 years of age in a recent comprehensive study of the causes of life-threatening diarrhea in children in sub-Saharan Africa and the Indian subcontinent (2). While amebiasis is still a significant problem in the first 2 years of life (2), the presence of E. histolytica-specific secretory IgA (sIgA) in breast milk correlates with a reduced risk of amebiasis in breastfeeding infants (3). The true global burden of E. histolytica infection remains unknown, but the frequency of infection can be staggering in areas of endemicity. In the Mirpur region of Dhaka, Bangladesh, greater than 50% of children have serologic evidence of E. histolytica infection by 5 years of age (4), and E. histolytica is the intestinal protozoan most frequently associated with diarrhea in this population (5). Invasive disease is characterized by dysentery and the potential for spread via the portal venous circulation to cause amebic liver abscesses (ALAs), which occur in approximately 1% of symptomatic cases (6).An effective E. histolytica vaccine could conceivably enable global eradication, since E. histolytica infects only humans and some higher nonhuman primates (7). There is currently no such vaccine, but some children with ...

show abstract

“…Adjuvant free form of this vaccine may fail to prevent renal shedding in infected animals [7]. Aluminum based adjuvant have been used for decades and their value in immunization plan is striking, their ability to activate strong humoral immunity [8,9]. Meanwhile, the oil adjuvant vaccine industry has an important role.…”

Section: Introductionmentioning

confidence: 99%

Development of Leptospira Killed Whole Culture Vaccine Using Different Adjuvants and Evaluation of Humoral Immune Response in Hamsters

Banihashemi¹,

Baradaran²,

Tebianian³

et al. 2013

J Vaccines Vaccin

View full text Add to dashboard Cite

Leptospirosis is an acute infectious disease caused by Leptospira spp. that produces a broad range of health problems mainly in developing world. In several affected countries, a major attempt has been begun to find a potent and effective vaccine. This is while; the available vaccines neither perused immunological memory nor confer cross-protection. Four-week-old male hamsters were subcutaneously inoculated with four-leptospiral vaccine and four-control adjuvant through a triple-injection regiment at fortnightly intervals. Animals were bled through the saphenous vein weekly until the seventh week. We have demonstrated that adjuvant plays a fundamental role in the type and extent of the immune responses raised by leptospiral vaccination. We strongly recommend selection of alum in any formulation of leptospiral vaccine.

show abstract

Immunogenicity and protective efficacy of recombinant Leptospira immunoglobulin-like protein B (rLigB) in a hamster challenge model

Cited by 88 publications

References 31 publications

A Conserved Region of Leptospiral Immunoglobulin-Like A and B Proteins as a DNA Vaccine Elicits a Prophylactic Immune Response against Leptospirosis

A Conserved Region of Leptospiral Immunoglobulin-Like A and B Proteins as a DNA Vaccine Elicits a Prophylactic Immune Response against Leptospirosis

Immunization with the Entamoeba histolytica Surface Metalloprotease EhMSP-1 Protects Hamsters from Amebic Liver Abscess

Development of Leptospira Killed Whole Culture Vaccine Using Different Adjuvants and Evaluation of Humoral Immune Response in Hamsters

Contact Info

Product

Resources

About